Dermatology Referral denials in California external review

In the California DMHC record, independent physician reviewers decided 18 published external-review cases involving Dermatology Referraland overturned the plan’s denial in 55.6%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.

California DMHC decisions
18
2002–2024
Overturned
55.6%
10 denials reversed
Typical time to a decision
18 days
Most land between 14 and 21 days
Handled as urgent
5.6%
Expedited when a delay would cause harm

What the reviewers wrote

Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for a referral to a dermatologist. A review of the provided records indicates that the patient was evaluated during an in-person visit resulting in a diagnosis of eczema herpeticum. Follow-up was by telephone. The provider recommended referral to dermatology since the patient’s known atopic dermatitis was not responding to the therapies provided. On the most recent visit, the patient was to start on clindamycin phosphate for atopic dermatitis, which is inconsistent with the treatment recommendations for patients in this clinical setting. In addition, adequate management of a complex dermatological condition such as atopic dermatitis requires in-person consultation to be appropriately examined.
Medical Necessity · 2023 · IMR MN23-38933
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for a dermatologist referral for evaluation of the enrollee who presented with a suspicious mole. Findings: The physician reviewer found that the request for coverage of dermatology referral should be approved. The size of the area is estimated at 2.5 cm. Dermatologists have specialized training in the evaluation of nevi and other skin growths. The medical literature shows that dermatologists are able to detect thinner lesions and are able to detect them at an earlier stage than those melanomas diagnosed by other physicians. Additionally, there is a family history of skin cancer, and the primary care provider recommended an evaluation by a dermatologist.
Medical Necessity · 2017 · IMR MN17-26685

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for a referral to a board-certified dermatologist who treats Mast Cell Activation Syndrome (MCAS).Mast cell activation syndrome refers to the clinical presentation of symptoms due to mast cell-mediated release. The diagnosis of MCAS requires that several criteria be met to confirm a diagnosis of MCAS. The first criterion requires episodic, objective signs and symptoms consistent with MCAS involving at least two organ systems. Subjective symptoms alone, such as fatigue and difficulty concentrating, in the absence of signs and symptoms in two other organ systems, do not warrant an evaluation for mast cell disorders. In addition, evidence of systemic mast cell-mediator release, corresponding temporally to the presence of symptoms with tryptase the most specific for mast cell activation.
Medical Necessity · 2024 · IMR MN24-40938
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for a dermatology referral. The Health Plan has denied this request indicating that the requested service is not medically necessary for treatment of the enrollee’s hypertrophic skin disorder.At issue in this case is whether the requested dermatology referral is medically necessary for treatment of the patient’s medical condition.Individuals may acquire a multitude of benign skin lesions over the course of a lifetime. Many of these lesions are easily visible, and patients often ask clinicians to confirm that new growths on the skin are benign. Most benign skin lesions are diagnosed on the basis of clinical appearance and history.
Medical Necessity · 2018 · IMR MN18-29902

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.

How to use this in your appeal

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Dermatology Referral, then check the rights and deadlines that apply to your plan.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Denied Dermatology Referral? Use the California record to prepare.

Explain my denial — freeStart my appeal · $9